394 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Arbor Trust Wealth Advisors LLC

Arbor Trust Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 394 shares of the medical research company’s stock, valued at approximately $209,000.

A number of other large investors have also recently added to or reduced their stakes in TMO. WCM Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after acquiring an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. lifted its position in shares of Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares in the last quarter. DMC Group LLC lifted its position in shares of Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares in the last quarter. S. R. Schill & Associates lifted its position in Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after buying an additional 792 shares in the last quarter. Finally, Check Capital Management Inc. CA purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth approximately $219,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TMO shares. Evercore ISI increased their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. HSBC initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, December 18th. They set a “buy” rating and a $610.00 price target on the stock. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Finally, Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $601.56.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $3.22 during midday trading on Tuesday, reaching $554.65. The stock had a trading volume of 1,010,297 shares, compared to its average volume of 1,539,256. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock has a market capitalization of $211.72 billion, a P/E ratio of 35.90, a PEG ratio of 2.38 and a beta of 0.80. The firm’s fifty day simple moving average is $571.79 and its 200-day simple moving average is $526.53. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period last year, the business posted $5.40 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.